USA Delivery yasekhaya, i-Canada Domestic Delivery, i-European Domestic Delivery

I-Orlistat powder

Isilinganiselwa:
5.00 koku 5 ngokusekelwe ku 1 isilinganiso ikhasimende
SKU: 96829-58-2. Isigaba:

I-AASraw inokukwazi ukuhlanganisa nokukhiqiza kusuka kugremu ukuya ku-oda lomkhulu we-Orlistat powder (i-96829-58-2), ngaphansi komthethonqubo we-CGMP kanye nesistimu yokulawula ikhwalithi.

I-Orlistat powder yi-derivative egcwele ye-lipstatin, i-inhibitor enamandla yemvelo ye-pancreatic lipases ehlukaniswe ne-bacterium Streptomyces toxytricini. I-Orlistat yisidakamizwa esenzelwe ukwelapha ukukhuluphala. Noma kunjalo, ngenxa yokwenza okulula okuyiyo ukuzinza, i-orlistat yakhethwa ngaphezu kwe-lipstatin yentuthuko njengesidakamizwa sokulwa nokukhuluphala ngokweqile.

Product Incazelo

Product Incazelo

UKUHLELWA KANYE Nesitatimende:

Le Material ithengiswa Ukusetshenziswa Kocwaningo Kuphela. Imibandela Yokuthengisa Faka isicelo. Hhayi Ukusetshenziswa Komuntu, noma Ezokwelapha, Izilwane, noma Ukusetshenziswa Kwasekhaya.

Ividiyo ye-Orlistat powder


Izinhlamvu ze-Orlistat powder ezisemqoka

Igama: I-Orlistat powder
CAS: 96829-58-2
Formula Yamamolekhula: C29H53NO5
Isisindo somzimba: 495.7
I-Melt Point: 50 ° C
Isitoreji Sokugcina: I-2-8 ° C
Umbala: powder emhlophe


Igama lomkhiqizo: I-Orlistat

IUPAC Name: [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate

Isingeniso se-Orlistat

Ingxenye engaphezu kwesigamu sezwe labantu abaye bazama uhlelo lokulawulwa kwesisindo, njengokudla ukudla, ukuzivocavoca, ukuhlinzwa, noma imithi. Zonke lezi zindlela zokulahlekelwa isisindo ziphumelela kuphela uma uthembekile kubo futhi ulandela imiyalelo kulabo abakugcina. Noma kunjalo, ukukhetha ukwelashwa noma imithi ingase ibe yingozi uma ungathathi izinyathelo eziphakeme zokuqapha.

Isakhiwo samakhemikhali se-Orlistat (ukuhlanganiswa kwe-3-D)

Isakhiwo samakhemikhali se-Orlistat (ukuhlanganiswa kwe-2-D)

Izakhiwo ze-Chemical ze-Orlistat

Igama lomhlaba I-Property Value
Ukubala kwe-Unit Integrated-Bonded 1
Isotope Atom Count 0
Ukubala okungenakulinganiswa kwesibalo 0
Ukubalwa kwe-Bond Stereocenter Count 0
Ukubala okungenakulinganiswa kwe-Atom 0
Count Count Stereocenter Count 4
Count Atom Count 35
Ukukhokha Okuhlelekile 0
I-Compound I-Canonicalized Yiqiniso
I-XLogP3-AA 10
IMisa yangempela I-495.392 g / mol
IMisa ye-Monoisotopic I-495.392 g / mol
Indawo ephezulu yePolological Polar I-81.7 A ^ 2
kushuba 579
I-Count Bond Count 23
I-Hydrogen Bond Acceptor Count 5
I-Hydrogen Bond Donor Count 1
isisindo Yamamolekhula I-495.745 g / mol

Incazelo elula ye-Orlistat powder

Okukodwa kwe imithi yokulahlekelwa isisindo ukuthi uzothola ekufuneni kwakho ukuthola izidakamizwa zokuphatha isisindo esiphezulu kakhulu i-Orlistat. Kulesi sibuyekezo se-Orlistat, uzothola ulwazi olubalulekile, kufaka phakathi ukuthi luyini, ukuthi lusebenza kanjani nokuthi lufanele lusetshenziswe kanjani, ngakho-ke unganquma uma kukukhetha kahle.

Yini i-Orlistat?

I-Orlistat, eyathengiswa njengemithi yokwelashwa ngaphansi kwegama lokuhweba i-Xenical, liyisidakamizwa sokulahlekelwa kwesisindo somuthi esakhiwe ukuze siphathe izinkinga zesisindo ezinzima ezifana nokukhuluphala, kanye nezinye izimo ezihlobene nesisindo. Yenziwa i-GlaxoSmithKline njengesidakamizwa esiphezulu se-Alli kokubili e-United States nase-United Kingdom.

Ama-formulations ajwayelekile we-Orlistat atholakala emazweni amaningana. Kusukela ku-2000, ihlelwe njengemithi ye-S3 ngaphezulu kwe-counter e-Australia. Ukwamukelwa kwe-Orlistat njengesidakamizwa esingaphezu kwe-counter kwaba yinkinga e-United States. Kwakuphikisana ngokuphindaphindiwe ekusebenzeni okusebenzayo nokuphepha ngethimba lokugqugquzela abathengi elibizwa ngokuthi i-Public Citizen.

Izenzo ze-Orlistat njenge-lipase inhibitor, okusho ukuthi ngokuvamile kuvimbela ukukhipha amafutha ekudleni, ngaleyo ndlela kuncishise inani lamakholori owathathayo. Njengeminye imithi eminingi yokulahlekelwa isisindo, I-Orlistat lenzelwe ukusetshenziswa ngokuhlanganiswa nezinye izindlela zokuphila ezifana nokuzivocavoca nokudla. Ucwaningo lwezokwelapha lubonisa ukuthi abantu abanamathele kule nhlanganisela banethuba lokulahlekelwa ngamakhilogremu amabili kuya kwamakhulu kunelawo angafaki isidakamizwa esithweni sabo sokulahlekelwa isisindo.

Esinye sezici ezifiselekayo mayelana ne-Orlistat ukuthi akusizi nje ukuthi ulahlekelwe isisindo kodwa futhi kunciphisa kahle ukucindezela kwegazi. Ukwengeza, lesi sidakamizwa sokuphathwa kwesisindo sikholwa ukuthi sivimbela ukuqala kohlobo lwe-2 yesifo sikashukela kubantu abakhuluphele ngendlela efanayo nendlela yokuphila eyenziwe ngayo.

Ngenkathi kunezinzuzo eziningana ze-Orlistat ukuze ujabule, kukhona neminye imiphumela emibi ye-Orlistat ukuze unake. Umphumela ovame kakhulu obikiwe wecilisi lokulahlekelwa isisindo ngu-steatorrhea. Lesi yisifo somzimba esisetshenziselwa i-oily, izihlalo ezixekethile. Izimpawu, ngenhlanhla, ziyancipha ngesikhathi.

Indlela ye-Orlistat yesenzo

I-Orlistat iyinhlanhla enamandla ye-Intestinal Lipase Inhibitor. Lesi sidakamizwa yisimiso esiphendukayo sokuvimbela isisindo samathambo omzimba. Isidakamizwa sakha isibopho esivumelanayo nesayithi elisebenzayo le-serine ku-pancreatic ne-gastric lipases, ngaleyo ndlela ivimbela isenzo sabo futhi ivimbele amafutha kusuka ekudleni kusukela ekugudluzeni i-hydrolyzed and absorbed. (NCI04).

Ngezimiso ezilula, i-Orlistat yenza kube lula ukulahlekelwa isisindo ngokunciphisa i-pancreatic ne-gastric lipases, okuyi-enzyme ebalulekile emathunjini ehlukumeza i-triglycerides. Lapho lezi lipases zivinjelwe, i-hydrolyzation ye-triglycerides kusuka ekudleni kwakho ibe yi-fatty acety acid acids.

Amaphilisi okudla athathwa ngomlomo futhi athathwa kanye; I-lipase inhibition yendawo yenzeke ngaphakathi kwepheshana le-GI. Amanani amancane kuphela omuthi adluliselwa emzimbeni, kanti iningi lezidakamizwa liqedwa ngamanzi.

Ucwaningo lwamuva luye lwathola i-Orlistat ukuba ibe namandla ekuvimbeleni i-enzyme ehilelekile ekusakazweni kwamangqamuzana omdlavuza owingozi. Noma kunjalo, imiphumela emibi engaba khona yomuthi (njengokuvimbela kwamanye amaseli angalindelekile noma ukungabi khona kwezinto ezimbi) kuphazamisa ukusetshenziswa kwayo njenge-antitumor agent ewusizo. Kwesinye isifundo, abacwaningi bathatha indlela yokwelashwa kwamakhemikhali ukuze bathole amathagethi amasha omuthi omuthi, kuhlanganise nezinhloso ezingekho.

Kumthamo ojwayelekile wesiguli we-120 mg izikhathi ezingu-3 ngosuku ngaphambi kokudla, i-orlistat isisindo sokulahlekelwa isisindo sigwemezela amaphesenti angu-30 wamafutha enomsoco ekungeneni emzimbeni. Ukuthatha amanani amaningi anganikeli imiphumela enamandla kakhulu.

Ukusetshenziswa kwe -Orlistatpowder

I-Orlistat isetshenziselwa njengesidakamizwa sokuphatha isisindo. Kuyisinqumo esihle kubantu abakhuluphele kakhulu noma abakhuluphele kakhulu. Le pilisi yokulahlekelwa isisindo inconywa ukuthi isetshenziswe ngabantu abanezinkinga zezokwelapha ezihlobene nesisindo. Ithembisa ukusiza abantu hhayi nje ukulahlekelwa isisindo, kodwa futhi kusiza ukuvimbela ukuba bangabuyeli emuva isisindo abalahlekile. Ngokwenza kanjalo, kusiza ukunciphisa ingozi yegazi eliphezulu, isifo sikashukela, isifo senhliziyo, nezinye izingozi eziningi zempilo ezihlobene nokukhuluphala.

Isilinganiso sokulahlekelwa isisindo ngemuva kokuthatha i-Orlistat ihluka ukusuka komuntu oyedwa kuya kwesinye. Abacwaningi abaqhuba ukuvivinyelwa komtholampilo okwedlule unyaka bathola ukuthi phakathi kwama-35.5 namaphesenti angu-54.8 wezifundo ezikwazi ukufeza amaphesenti angu-5 ukwehla okukhulu emzimbeni, nakuba kungasiwo wonke umthamo olahlekile owawukhulu kakhulu. Mayelana ne-16.4% -24.8 yezihloko eziphumelele ukufeza okungenani amaphesenti angu-10 wehla emanzini omzimba. Lapho izihloko ziyeka ukuthatha i-Orlistat, inamba enkulu yawo yaphinde yafika ku-35 amaphesenti wesisindo abaye bakwazi ukulahlekelwa.

Isilinganiso se-Orlistat

I-Orlistat iza ngesimo se-turquoise, i-hard-gelatin capsules equkethe amapelisi we-powder futhi iluhlu lwe-120-mg. Isilinganiso samanje nsuku zonke sinconywa ama-capsules amathathu ngosuku. Akufanele uthathe amaphilisi amathathu ekuhambeni, kodwa esikhundleni salokho uthathe ithebhulethi ngayinye ngesidlo esikhulu esineziqu, okungukuthi, enye yokudla kwasekuseni, enye yokudla kwasemini, nesinye isidlo sakusihlwa. Ungathatha iphilisi ngalinye ngokudla noma kuze kube ihora elilodwa emva kokudla. Uma kwenzeka ukudla kungabikho, noma uma ukudla kwakho kungenamafutha, umthamo we-Orlistat ungashiywa. Amanani angaphezu kwesilinganiso sempilo yansuku zonke asikatholakalanga ukuhlinzeka nganoma iyiphi inzuzo eyengeziwe.

I-Orlistat iphumelela kakhulu uma ihlangene namanye amasu okulahlekelwa kwesisindo njengokunamathela ekudleni okunomsoco, okuncishisiwe-khalori nokuzivocavoca njalo. Ukwaziswa ukuthi uthathe iphilisi yokulahlekelwa isisindo ngokudla okuqukethe cishe amaphesenti angu-30 amakholori avela kumafutha. Imiphumela yomuthi ibonakala ngokushesha ngemuva kwamahora angu-24-48 ngemva kokuthatha umthamo.

I-Orlistat itholakale isebenza kahle ekunciphiseni ukumuncwa kwamavithamini athile anamafutha amaningi kanye ne-beta-carotene. Ngakho-ke, abantu abathatha iphilisi bayelulekwa ukuba bayithathe kanye ne-vitamin amaningi enezakhi zamavithamini ezinamafutha amaningi ukuqinisekisa ukudla okwanele. Kunconywa ukuthi isithasiselo sevithamini singathathwa okungenani amahora amabili ngaphambi noma ngemuva kokuthatha i-Orlistat.

Ngokuqondene nalabo abagulayo bethola ukwelashwa kwe-cyclosporine, bayelulekwa ukuba benze i-cyclosporine okungenani amahora angu-3 ngemuva kokuthatha i-Orlistat. Kulabo abathola ukwelashwa kwe-levothyroxine, bakhuthazwa ukuba baphathe ukwelashwa kwe-levothyroxine okungenani amahora angu-4 ngemuva kokuthatha i-Orlistat. Labo abasebenzisa kokubili i-Orlistat ne-levothyroxine kufanele baqaphelwe ngokucophelela ngenxa yezinguquko emsebenzini we -roid.

I-OrlistatIzinketho

Ngaphambilini, i-orlistat yayithathwe ngokungaphansi kwemithi kadokotela noma wemithi. Kodwa-ke, ku-2007, i-US Yokudla Nezidakamizwa Zokulawulwa Kwezidakamizwa yawugunyaza emakethe engaphezu kwe-counter, ngakho-ke, okwenza itholakale wonke umuntu.

Hlola noma yikuphi ukusabela okweqile

Ngaphambi kokuthatha lesi sidakamizwa, kuphakanyiswa ukuba ukhulume nodokotela wakho nganoma yikuphi ukuphendula kwe-hypersensitivity ongayithola. I-Orlistat iqukethe izithako ezingasebenzi, ezingase zingathandeki kuwe, okuholela ekusebenzeni okukhulu kwe-allergen kanye nemiphumela emibi. Ezinye zazo zihlanganisa i-cellulose, i-microcrystalline, i-gelatin, i-silica, ne-sodium isitashi ye-glycolate.

Cabanga ngomlando wakho wezokwelapha

Udinga ukwabelana nekhemisi noma udokotela wakho mayelana nanoma yiziphi izimo zezokwelapha ongase ube nazo. Lokhu kungenxa yokuthi i-orlistat iphikisana nezinkinga ezithile nezinkinga, ikakhulukazi lezo ezihambisana nokugaya.

Uma uhlangabezana nanoma yiziphi izimo ezingezansi, kuphakanyiswa ukuba ufune ulwazi oluthe xaxa kusuka kochwepheshe.

Malabsorption syndrome

Lokhu kungavamile ukuthi kunomthwalo wokungenwa okwanele kwezakhi zokudla eceleni kwesistimu ye-GIT. Kufanele uqaphele ukuthi i-orlistat ngokwayo isebenza ngokuvimbela ukugaya kwamafutha. Ngakho-ke, lokhu kuzophela kube yingozi kakhulu kunoma ngubani othatha lesi sidakamizwa, kodwa bahlupheka nge-malabsorption syndrome.

Isifo senhliziyo noma i-cholestasis

Lesi yisimo lapho kunokuvinjwa kokugeleza kwe-bile kwesibindi. Kunemibiko eminingana exhumanisa i-orlistat nokulimala kwesibindi okukhulu, noma ivela ezimweni ezingavamile noma ngaphansi komthamo ophakeme.

Isifo se-Gallbladder

Lokhu kufaka phakathi i-cholecystectomy ne-syndromes ehambisanayo.

Ezinye izimo zezempilo okufanele ukhulume kumakhemikhali wakho zibandakanya ukutheleleka ngegciwane lesandulela ngculazi, isifo se-thyroid, amatshe ezinso, ukuwayeka noma ukuphazamiseka kwamagciwane. Lapho behlukunyezwa noma bexhumene, i-orlistat ingaqeda ukungalingani ukwelashwa kwe-antiepileptic ngokuphazamisa ukungena.

kwemikhuba yokudla

Ezinye zalezi zinkinga ziyi-bulimia ne-anorexia. Futhi, asikho isidingo sokuthatha i-orlistat uma ungapheli ngokweqile.

Ezinye imithi

Kuwukuhlakanipha ukukwazisa udokotela wakho uma ngabe kuneminye imithi ikakhulukazi leyo engase ikhusele isimiso somzimba sokuzivikela. Ukusebenzisana kwezidakamizwa kuzophazamisa i-pharmacokinetics, okuholela ekwenzeni ukwanda noma ukwehla komthelela kubo. Ngokwesibonelo, i-orlistat izophazamisa ngaso sonke isikhathi indlela yokwelashwa okubekwe khona ukufakelwa komzimba.

Uma u-cyclosporine, udokotela wakho cishe uzokutshela ukuthi ugweme i-orlistat. Noma kunjalo, usengakwazi ukuyilawula kuphela ngemilayezo eqinile. Ukuze ube ohlangothini oluphephile, kufanele uthathe okungenani amahora amabili ngaphambi kwalesi sidakamizwa sokuphatha isisindo noma amahora amabili kamuva.

Ukwengeza, kufanele ukhulume yonke imithi kadokotela kanye nemithi engavumelekile, izithako zokudla, amavithamini, ama-anticoagulants, noma imikhiqizo yemithi ongase uyithathe.

Abesifazane abakhulelwe nabancelisayo

Le mithi yokuphatha isisindo akuyona yabomama abalindele, noma ubani ohlela ukukhulelwa, noma ukuncelisa ingane. Isidakamizwa akunakwenzeka ukuthi sibe nomthelela wokulahlekelwa isisindo futhi kuzophela ukulimaza ingane.

Nakuba kungakacaci ukuthi i-orlistat idlulela esifubeni sikamama, kungcono ukuyigweme futhi uzizwe uphephile, kunokudabuka.

Izifo zesifo sikashukela

I-Orlistat yilokho umuntu onesifo sikashukela angadinga ukuthuthukisa nokulawula ushukela wegazi nokuthuthukisa ukubekezelelana kwe-glucose. Noma kunjalo, kuzodingeka uqaphele amazinga kashukela njalo futhi uvakashele udokotela njalo. Ukwenza kanjalo kukusiza ukuba wazi ukuthi kufanele ulungise yini imishanguzo yesifo sikashukela, ukudla okulungile, kanye nohlelo lokuzivocavoca okufanele uthathe.

I-Orlistat Side Effects

Njengezokwelapha eziningi, i-orlistat inezimo zayo ezimbi. Umthelela ohlangothini oluyinhloko uhlale ubhekwa emisebenzini yemilenze. Noma kunjalo, lokhu kungabonakala kuphela phakathi kwamasonto ambalwa okuqala ngokuthatha isidakamizwa sokulahlekelwa isisindo.

Kwabanye abantu, izimpawu zingase zishintshe ngesikhathi abanye; ingase iqhubeke phakathi kokuthatha i-orlistat. Ngalesi sikhathi, kuwukuhlakanipha ukutshela udokotela wakho. Uma uvumelanisa ngokwengeziwe ukudla okunamafutha aphansi, cishe kunemiphumela emibi ukunciphisa.

Nanka eminye imiphumela ejwayelekile;

I-Steatorrhea

Yize kungenabungozi, i-steatorrhea yikutholakala kwamafutha namafutha angaphezu kwesisindo. Njengoba i-orlistat ivimbela i-lipases, ngeke kube khona ukuxakwa kwamafutha e-acids mahhala. Ngenxa yalokho, udoti luzovela oily futhi bulky.

Ukuze ulawule le mphumela, umuntu kufanele agweme ukudla okunezikhalori namazinga aphezulu e-fat. Ngokwezilinganiso ze-FDA, inani kufanele libe ngaphakathi kwe-0.53 ounces futhi lingadluli i-30%.

Flatulence

Ezimweni eziningi, igesi iphuma ngokuphuma kwamagesi. Kuzodingeka uhlole izembatho zakho noma izingubo zangaphansi zokuthola indawo ye-oily spotting.

  • Ukungathembeki kwamaFecal

Eziphuthumayo, eziphuthumayo, kanye nokunyakaza kwezibilini njalo

  • Ukukhathazeka nobuhlungu besisu
  • Umjikelezo ongavamile wokuya esikhathini
  • Amazinga kashukela ephansi aphansi

Lokhu kuvamile phakathi kwabantu abanesifo sikashukela sohlobo II.

  • Ukulimala okukhulu kwesibindi

Amacala anjalo awavamile kodwa avele uma unezinkinga ezithile zesibindi, noma uthatha umthamo ophezulu. Ngo-2010, i-FDA yafaka isexwayiso sokuphepha kumalebula we-orlistat, akhombisa ubungozi bokulimala kwesibindi okungenzeka.

Kodwa-ke, lo mphumela omubi useyimpikiswano ngokubheka ukuthi olunye ucwaningo lwamacala ashicilelwe kwiBritish Medical Journal lukhombisa okuhlukile.

Ezinye zezibonakaliso eziyisixwayiso zesifo sesibindi zihlanganisa ukuhlanza, ubuhlungu besisu, isikhumba esiphuzi, nomchamo omnyama.

Ukuphendula kwe-allergen

Kuyinto engavamile ukubhekana nanoma iyiphi i-hypersensitivity noma impendulo ye-allergen lapho uthatha i-orlistat isisindo sokulahlekelwa isisindo. Kwabanye abantu, izithako ezingasebenzi ezingatholakali isisindo sokuqhwaga, ukuchiza, ukuqhuma, ukuvuvukala komzimba, ukuphefumula kanzima, noma isizungu.

Eminye imiphumela emibi engafani kakhulu ifaka ukukhathazeka, ikhanda, ukuvuvukala, ukungakhululeki okuphathelene nokukhathala, ukukhathala, ukuthambeka okuphansi, kanye namagall. Uma uhlangabezana nezimpawu ezinzima, kufanele wazise udokotela wakho ngokushesha noma ubike uHlelo Lokubika lwe-FDA.

Isiqinisekiso sokugcina ku-Orlistat powder

Nakuba i-orlistat inemiphumela emibi embalwa, kuyindlela yokwelapha isisindo esihle kakhulu esizoletha imiphumela kungakapheli amasonto amabili. Imfihlo yokuzuza kulo muthi ilandela imiyalelo, ukuqonda izinyathelo zokuqapha, nokuhlola ekudleni kwakho.

Njengoba uthatha i-orlistat, kubalulekile ukulandela uhlelo lokudla okunempilo, kudla amanoni angaphansi, ama-calorie aphansi, nokuzivocavoca njalo. Ukudla okufanele kufanele kuhlanganise izithelo, imifino kanye nezinhlamvu eziningi. Ukwengeza, kufanele uhlanganise nokudla kwakho nemikhiqizo ye-multivitamin ebalulekile kusukela i-orlistat ivimbela ukumunwa kwamavithamini amaningi anamafutha.

Uma ungabaza, ungaxhumana nomuthi wemithi noma udokotela ukuze uthole imiyalelo eyengeziwe. Ngaphandle kwalokho, ungaxhumana ne-US Food and Drug Administration nganoma yikuphi ukubuza noma ukubika imiphumela engozini yokuphila, engabhalwanga.


Indlela yokuthenga I-Orlistat powder (96829-58-2) kusuka ku-AASraw

1.Ukuxhumana nathi nge-imeyili yethu uhlelo lokuphenya, noma isibhakabhaka se-inthanethiummeleli wenkonzo yamakhasimende (CSR).
I-2.Ukusihlinzekela ngobuningi bakho kanye nekheli lakho elibuziwe.
I-3.I-CSR yethu izokunikeza ikhothethini, isikhathi sokukhokha, inombolo yokulandelela, izindlela zokulethwa kanye nosuku lokufika olulinganisiwe (i-ETA).
I-4.Inkokhelo eyenziwe futhi izimpahla zizothunyelwa kumahora we-12 (Ukuhleleka ngaphakathi kwe-10kg).
Ama-5.Goods athola futhi anikeze imibono.

UKUHLELWA KANYE Nesitatimende:

Le Material ithengiswa Ukusetshenziswa Kocwaningo Kuphela. Imibandela Yokuthengisa Faka isicelo. Hhayi Ukusetshenziswa Komuntu, noma Ezokwelapha, Izilwane, noma Ukusetshenziswa Kwasekhaya.


COA

I-COA 96829-58-2 Uhlobo lwe-Orlistat AASRAW

I-HNMR

I-Orlistat powder emnyama (96829-58-2) hplc =98% | I-AASraw Fat Loss powder

I-AASraw inikeza ubumsulwa 99% Orlistat i-powder eluhlaza kubanikazi bomzimba noma amalebhu angaphansi komhlaba okusetshenziselwa ngomlomo.

Ungadliwa

Okubhekiselweyo nokuhlungwa komkhiqizo

Ngabe u-Orlistat usebenza kanjani njengomuthi wokulahlekelwa kwesisindo?

lwezincwadi

Zhi J, Melia AT, Eggers H, Joly R, Patel IH (1995). "Ukubuyekezwa kwe-orlistat encane yokwakheka kwe-systemic, i-lipase inhibitor, kumavolontiya anempilo". J Clin Pharmacol. 35 (11): 1103-8

  1. I-Garcia SB, i-Barros LT, i-Turatti A, et al. I-Orlistat ye-anti-obesity ehlobene nokukhushulwa ihlotshaniswa nokwandisa kumakaki we-colonic preneoplastic kumagundane aphathwe nge-carcinogen yamakhemikhali. I-Cancer Lett. 2006; 240: 221-4.
  2. I-FDA ivumela ama-capsules ama-orlistat 60 mg) "Over-The-Counter" (PDF) (Ukukhishwa kwezindaba). I-PRNewswire. 7 February 2007
  3. UMittendorfer B, Ostlund RE, Jr, Patterson BW, et al. I-Orlistat ivimbela ukumuncwa kokudla kwe-cholesterol. Obes Res 2001; 9: 599-604
  4. I-Peng-Yu, Yang; I-Kai, Liu; Mun Hong, Ngai; J.Lear, uMartin; R.Wenk, uMarkus; S.Qin, Yao (2010). "Ukuprofetha kwe-proteome esekelwe emisebenzini yemikhakha yamaselula engaba yi-Orlistat-i-FDA evunyelwe izidakamizwa nemisebenzi yokulwa ne-tumor". I-Journal ye-American Chemical Society. 132 (2): 656-66.